Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Share-based Compensation (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Share-based Compensation for 11 consecutive years, with $16.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 57.75% to $16.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.2 million through Dec 2025, down 48.0% year-over-year, with the annual reading at $80.2 million for FY2025, 48.0% down from the prior year.
  • Share-based Compensation for Q4 2025 was $16.7 million at Intellia Therapeutics, down from $19.6 million in the prior quarter.
  • The five-year high for Share-based Compensation was $40.9 million in Q2 2024, with the low at $6.4 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $25.3 million, with a median of $23.8 million recorded in 2022.
  • The sharpest move saw Share-based Compensation skyrocketed 187.84% in 2022, then plummeted 57.75% in 2025.
  • Over 5 years, Share-based Compensation stood at $14.6 million in 2021, then soared by 69.12% to $24.6 million in 2022, then skyrocketed by 42.3% to $35.0 million in 2023, then increased by 13.05% to $39.6 million in 2024, then tumbled by 57.75% to $16.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $16.7 million, $19.6 million, and $22.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.